Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
Advertise
UsernamePublicRestriction
Tags:
Companies

Avila Therapeutics appoints first CEO

This article was originally published in Scrip

  • News

Executive Summary

Avila Therapeutics (US), an emerging biopharmaceutical company developing covalent drugs, has appointed Katrine Bosley chief executive officer. She joins from Adnexus, where she served as vice-president of business development and later as vice-president of strategic operations.

You may also be interested in...



EMA Prepares Approval Verdict On Beovu, Idhifa, Recarbrio

Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.

New Zealand Reverse-Switches Codeine Judging Risks Outweigh Benefits

New Zealand is the latest country to reverse-switch all codeine-containing OTC drugs to prescription-only status following a protracted consultation process, during which industry's protestations fell on deaf ears.

Julphar Focuses On Quality As Carle Departs

As its CEO Jerome Carle steps down following a 67% slump in sales to date this year, UAE-based Julphar is hopeful of putting manufacturing problems behind it under a new management team.

Table

View full table

Topics

Tags:
Companies
UsernamePublicRestriction

Register

SC002104

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By